Payment overview · 2025
General Payments
$355.68
16 reported records · 8 companies
Healthcare provider profile · identity verified
Eric C Isenman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MELBOURNE, FL · NPI 1609931187
Verified facts
What the public records show
CMS Open Payments records show Eric C Isenman, MD received $355.68 in general payments during 2025 across 16 reported records.
Phathom Pharmaceuticals, Inc. accounted for 36.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $128.87 | 36.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $69.85 | 19.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.01 | 13.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.00 | 11.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.51 | 5.2% | 1 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $17.75 | 5.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.04 | 4.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.65 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $355.68 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $128.87 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.01 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $42.00 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.81 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.81 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.10 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 23 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
230 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 717 | 208 |
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 421 | 121 |
| Lisinopril | Lisinopril | 313 | 92 |
| Montelukast Sodium | Montelukast Sodium | 312 | 92 |
| Losartan Potassium | Losartan Potassium | 254 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 83 |
| Gabapentin | Gabapentin | 234 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 231 | 77 |
| Eliquis | Apixaban | 230 | 42 |
| Omeprazole | Omeprazole | 226 | 71 |
| Famotidine | Famotidine | 220 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 211 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 209 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 206 | 64 |
| Metformin Hcl | Metformin Hcl | 190 | 58 |
| Alprazolam | Alprazolam | 186 | 73 |
| Furosemide | Furosemide | 183 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 47 |
| Simvastatin | Simvastatin | 149 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 135 | 19 |
| Valsartan | Valsartan | 131 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 55 |
| Potassium Chloride | Potassium Chloride | 119 | 39 |
| Methylprednisolone | Methylprednisolone | 114 | 88 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 36 |
| Finasteride | Finasteride | 99 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 98 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 36 |
| Tramadol Hcl | Tramadol Hcl | 94 | 30 |
| Spironolactone | Spironolactone | 91 | 24 |
| Jardiance | Empagliflozin | 90 | 23 |
| Allopurinol | Allopurinol | 87 | 23 |
| Prednisone | Prednisone | 86 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 24 |
| Lorazepam | Lorazepam | 85 | 20 |
| Cefuroxime | Cefuroxime Axetil | 80 | 44 |
| Trazodone Hcl | Trazodone Hcl | 79 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 23 |
| Glipizide | Glipizide | 75 | 23 |
| Ipratropium Bromide | Ipratropium Bromide | 75 | 28 |
| Carvedilol | Carvedilol | 74 | 20 |
| Meloxicam | Meloxicam | 74 | 27 |
| Ozempic | Semaglutide | 74 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 20 |
| Mirtazapine | Mirtazapine | 69 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 48 |
| Ezetimibe | Ezetimibe | 61 | 16 |
| Sertraline Hcl | Sertraline Hcl | 60 | 23 |
| Memantine Hcl | Memantine Hcl | 55 | 12 |
| Bupropion Xl | Bupropion Hcl | 53 | 16 |
| Synthroid | Levothyroxine Sodium | 53 | 11 |
| Lovastatin | Lovastatin | 52 | 16 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 50 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 48 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 14 |
| Celecoxib | Celecoxib | 47 | 19 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Clonazepam | Clonazepam | 46 | 11 |
| Azithromycin | Azithromycin | 44 | 36 |
| Xarelto | Rivaroxaban | 44 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 17 |
| Benazepril Hcl | Benazepril Hcl | 42 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 32 |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 14 |
| Glipizide Er | Glipizide | 40 | 11 |
| Estradiol | Estradiol | 39 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 20 |
| Atenolol | Atenolol | 38 | 12 |
| Irbesartan | Irbesartan | 38 | 13 |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Diazepam | Diazepam | 35 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 32 | 29 |
| Testosterone | Testosterone | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | 12 |
| Pregabalin | Pregabalin | 30 | 11 |
| Bumetanide | Bumetanide | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 11 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | 18 |
| Temazepam | Temazepam | 29 | 11 |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 12 |
| Torsemide | Torsemide | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Naproxen | Naproxen | 23 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 17 |
| Colchicine | Colchicine | 21 | 11 |
| Hydrocortisone | Hydrocortisone | 21 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | 11 |
| Primidone | Primidone | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 13 |
| Erythromycin Ethylsuccinate | Erythromycin Ethylsuccinate | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Nucynta Er | Tapentadol Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 11 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $355.68 · 16 records | Phathom Pharmaceuticals, Inc. | BREZTRI, EVENITY, MOUNJARO, OTEZLA, Ozempic, PAXLOVID, REPATHA, Rybelsus, UBRELVY, VOQUEZNA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error